Eribulin mesylate + Eribulin mesylate + Eribulin mesylate
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Jul 13, 2016 → Aug 16, 2019
NCT ID
NCT02753595About Eribulin mesylate + Eribulin mesylate + Eribulin mesylate
Eribulin mesylate + Eribulin mesylate + Eribulin mesylate is a phase 1/2 stage product being developed by Eisai for Metastatic Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02753595. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02753595 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Metastatic Breast Cancer